CD8A and neoplasm: The EGFR inhibitor gefitinib enhances the efficacy of PD-1 monoclonal antibody by reducing the interaction between PD-L1 and PD-1, enhancing IL-2 expression in T cells, promoting the activation of CD8+ TILs and improving T cell-mediated tumor cell killing [205].